Second-quarter growth in Europe was 4.6%, driven by a 37.5% rise in Eastern Europe, which since beginning of April has included Zentiva (net sales: euro 163 million). Over the first half, net sales in Europe rose by 1.8%, with growth affected mainly by ongoing competition from generics of Eloxatin((R)).
The United States recorded second-quarter growth of 5.4%, driven by fine performances from Lantus((R)) (up 28.7%), Taxotere((R)) (up 9.6%) and Eloxatin((R)) (up 10.0%). Excluding H5N1 contracts, growth was 11.3%. Over the first half as a whole, net sales were flat due to the end of commercialization of Copaxone((R)) by sanofi-aventis effective April 1, 2008.
In the Other Countries region, second-quarter net sales rose by 11.2%, reflecting an excellent performance in Vaccines (up 27.2% at euro 209 million) and dynamic growth in Asia-Pacific (up 18.2%) and the Middle East (up 25.5%). Second-quarter net sales in China were up 40.6% at euro 134 million. Net sales in Japan rose by 6.6% to euro 442 million, boosted by the continuing success
Copyright©2009 PR Newswire.
All rights reserved